Skip to main content
SpringerLink
Log in

Carboxyamidotriazole, an Inhibitor of Nonvoltage-Operated Calcium Entry

Single-Agent and Combination Therapy for Ovarian Carcinoma

  • Chapter
Combination Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 526 Accesses

Abstract

Conventional cytotoxic chemotherapy has reached a critical point in cancer therapy. While marked improvements in treatment outcome and remission frequency have been made, improvement in cure rate for advanced-stage cancers remains unchanged. This sobering statistic has led investigators to search for novel targets and intervention combinations for the prevention and treatment of cancer. The advent of combination carboplatin/paclitaxel for the adjuvant treatment of ovarian cancer has led to improved response rates and prolonged survival (1). However, over 60% of patients relapse, and the 5-yr survival rate is still below 50%.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.

    Article  PubMed  CAS  Google Scholar 

  2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.

    Article  PubMed  CAS  Google Scholar 

  3. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375–379.

    Article  PubMed  CAS  Google Scholar 

  4. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000;6:324–329.

    Article  PubMed  CAS  Google Scholar 

  5. Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 1980;77:3494–3498.

    Article  PubMed  CAS  Google Scholar 

  6. Silletti S, Raz A. Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis. Curr Top Microbiol Immunol 1996;213(Pt 2):137–169.

    PubMed  CAS  Google Scholar 

  7. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and firoblasts in carcinoma formation. Exp Cell Res 2001;264:169–184.

    Article  PubMed  CAS  Google Scholar 

  8. Kohn EC, Liotta LA, Schiffmann E. Autocrine motility factor stimulates a three-fold increase in inositol trisphosphate in human melanoma cells. Biochem Biophys Res Commun 1990;166:757–764.

    Article  PubMed  CAS  Google Scholar 

  9. Liotta LA. Tumor invasion and metastases—role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986;46:1–7.

    Article  PubMed  CAS  Google Scholar 

  10. Liotta LA, Mandler R, Murano G, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 1986;83:3302–3306.

    Article  PubMed  CAS  Google Scholar 

  11. Aznavoorian S, Stracke ML, Krutzsch H, Schiffmann E, Liotta LA. Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol 1990;110:1427–1438.

    Article  PubMed  CAS  Google Scholar 

  12. Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267:2524–2529.

    PubMed  CAS  Google Scholar 

  13. Stracke M, Liotta LA, Schiffmann E. The role of autotaxin and other motility stimulating factors in the regulation of tumor cell motility. Symp Soc Exp Biol 1993;47:197–214.

    PubMed  CAS  Google Scholar 

  14. Nam SW, Clair T, Kim YS, et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 2001;61:6938–6944.

    PubMed  CAS  Google Scholar 

  15. Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000;19:241–247.

    Article  PubMed  CAS  Google Scholar 

  16. Clair T, Lee HY, Liotta LA, Stracke ML. Autotaxin is an exoenzyme possessing 5′-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities. J Biol Chem 1997;272:996–1001.

    Article  PubMed  CAS  Google Scholar 

  17. Burch RM, Luini A, Axelrod J. Phospholipase A2 and phospholipase C are activated by distinct GTP-binding proteins in response to alpha 1-adrenergic stimulation in FRTL5 thyroid cells. Proc Natl Acad Sci USA 1986;83:7201–7205.

    Article  PubMed  CAS  Google Scholar 

  18. Berridge MJ, Heslop JP, Irvine RF, Brown KD. Inositol trisphosphate formation and calcium mobilization in Swiss 3T3 cells in response to platelet-derived growth factor. Biochem J 1984;222:195–201.

    PubMed  CAS  Google Scholar 

  19. Berridge MJ. Calcium signalling and cell proliferation. Bioessays 1995;17:491–500.

    Article  PubMed  CAS  Google Scholar 

  20. Hernandez M, Barrero MJ, Crespo MS, Nieto ML. Lysophosphatidic acid inhibits Ca2+ signaling in response to epidermal growth factor receptor stimulation in human astrocytoma cells by a mechanism involving phospholipase C(gamma) and a G(alpha) protein. J Neurochem 2000;75:1575–1582.

    Article  PubMed  CAS  Google Scholar 

  21. Wu J, Cunnick JM. Trans-regulation of epidermal growth factor receptor by lysophosphatidic acid and G protein-coupled receptors. Biochim Biophys Acta 2002;1582:100–106.

    PubMed  CAS  Google Scholar 

  22. Putney JW, Jr. A model for receptor-regulated calcium entry. Cell Calcium 1986;7:1–12.

    Article  PubMed  CAS  Google Scholar 

  23. Schwartz GK, Redwood SM, Ohnuma T, Holland JF, Droller MJ, Liu BC. Inhibition of invasion of invasive human bladder carcinoma cells by protein kinase C inhibitor staurosporine. J Natl Cancer Inst 1990;82:1753–1756.

    Article  PubMed  CAS  Google Scholar 

  24. Schwartz GK, Jiang J, Kelsen D, Albino AP. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 1993;85:402–407.

    Article  PubMed  CAS  Google Scholar 

  25. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, et al. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J Natl Cancer Inst 1995;87:1394–1399.

    Article  PubMed  CAS  Google Scholar 

  26. Kohn EC, Liotta LA. L651582: a novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 1990;82:54–60.

    Article  PubMed  CAS  Google Scholar 

  27. Alonso-Torre SR, Alvarez J, Montero M, Sanchez A, Garcia-Sancho J. Control of Ca2+ entry into HL60 and U937 human leukaemia cells by the filling state of the intracellular Ca2+ stores. Biochem J 1993;289( Pt 3):761–766.

    PubMed  CAS  Google Scholar 

  28. Villalobos C, Fonteriz R, Lopez MG, Garcia AG, Garcia-Sancho J. Inhibition of voltage-gated Ca2+ entry into GH3 and chromaffin cells by imidazole antimycotics and other cytochrome P450 blockers. FASEB J 1992;6:2742–2747.

    PubMed  CAS  Google Scholar 

  29. Hornstein EH, Vassilopoulos D, Thomas DE, Friedman FK, Tsokos GC. Modulation of human T-lymphocyte plasma membrane Ca2+ permeability by imidazole antimycotics. Immunopharmacol Immunotoxicol 1996;18:237–245.

    PubMed  CAS  Google Scholar 

  30. Coupry I, Armsby CC, Alper SL, Brugnara C, Parini A. Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I1 and I2 binding sites. Eur J Pharmacol 1996;295:109–112.

    Article  PubMed  CAS  Google Scholar 

  31. Brugnara C, Armsby CC, Sakamoto M, Rifai N, Alper SL, Platt O. Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther 1995;273:266–272.

    PubMed  CAS  Google Scholar 

  32. Brugnara C, De Franceschi L, Armsby CC, et al. A new therapeutic approach for sickle cell disease. Blockade of the red cell Ca(2+)-activated K+ channel by clotrimazole. Ann N Y Acad Sci 1995;763:262–271.

    Article  PubMed  CAS  Google Scholar 

  33. Montero M, Garcia-Sancho J, Alvarez J. Comparative effects of cytochrome P-450 inhibitors on Ca2+ and Mn2+ entry induced by agonists or by emptying the Ca2+ stores of human neutrophils. Biochim Biophys Acta 1993;1177:127–133.

    Article  PubMed  CAS  Google Scholar 

  34. Sargeant P, Clarkson WD, Sage SO, Heemskerk JW. Calcium influx evoked by Ca2+ store depletion in human platelets is more susceptible to cytochrome P-450 inhibitors than receptor-mediated calcium entry. Cell Calcium 1992;13:553–564.

    Article  PubMed  CAS  Google Scholar 

  35. Najid A, Ratinaud MH. Comparative studies of steroidogenesis inhibitors (econazole, ketoconazole) on human breast cancer MCF-7 cell proliferation by growth experiments, thymidine incorporation and flow cytometric DNA analysis. Tumori 1991;77:385–390.

    PubMed  CAS  Google Scholar 

  36. Bruserud O. Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia. Int Immunopharmacol 2001;1:2183–2195.

    Article  PubMed  CAS  Google Scholar 

  37. Benzaquen LR, Brugnara C, Byers HR, Gatton-Celli S, Halperin JA. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat Med 1995;1:534–540.

    Article  PubMed  CAS  Google Scholar 

  38. Zhang Y, Crump M, Berge SA. Purging of contaminating breast cancer cells from hematopoietic progenitor cell preparations using activation enhanced cell death. Breast Cancer Res Treat 2002;72:265–278.

    Article  PubMed  CAS  Google Scholar 

  39. Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001;90:1204–1207.

    Article  PubMed  CAS  Google Scholar 

  40. Ayub M, Levell MJ. Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. J Steroid Biochem 1987;28:521–531.

    Article  PubMed  CAS  Google Scholar 

  41. Stalla GK, Stalla J, von Werder K, et al. Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology 1989;125:699–706.

    Article  PubMed  CAS  Google Scholar 

  42. Gupta S, Kim J, Gollapudi S. Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. J Clin Invest 1991;87:1467–1469.

    PubMed  CAS  Google Scholar 

  43. Felder CC, Ma AL, Liotta LA, Kohn EC. The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther 1991;257:967–971.

    PubMed  CAS  Google Scholar 

  44. Felder CC, MacArthur L, Ma AL, Gusovsky F, Kohn EC. Tumor-suppressor function of muscarinic acetylcholine receptors is associated with activation of receptor-operated calcium influx. Proc Natl Acad Sci USA 1993;90:1706–1710.

    Article  PubMed  CAS  Google Scholar 

  45. Gusovsky F, Lueders JE, Kohn EC, Felder CC. Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-gamma. An alternative mechanism for cholinergic-induced phosphoinositide breakdown. J Biol Chem 1993;268:7768–7772.

    PubMed  CAS  Google Scholar 

  46. Kohn EC, Felder CC, Jacobs W, et al. Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res 1994;54:935–942.

    PubMed  CAS  Google Scholar 

  47. Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, Liotta LA. Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 1994;269:21,505–21,511.

    PubMed  CAS  Google Scholar 

  48. Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA. Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 1995;92:1307–1311.

    Article  PubMed  CAS  Google Scholar 

  49. Alessandro R, Masiero L, Lapidos K, Spoonster J, Kohn EC. Endothelial cell spreading on type IV collagen and spreading-induced FAK phosphorylation is regulated by Ca2+ influx. Biochem Biophys Res Commun 1998;248:635–640.

    Article  PubMed  CAS  Google Scholar 

  50. Masiero L, Lapidos KA, Ambudkar I, Kohn EC. Regulation of the RhoA pathway in human endothelial cell spreading on type IV collagen: role of calcium influx. J Cell Sci 1999;112:3205–3213.

    PubMed  CAS  Google Scholar 

  51. Bauer KS, Figg WD, Hamilton JM, et al. A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin Cancer Res 1999;5:2324–2329.

    PubMed  CAS  Google Scholar 

  52. Luzzi KJ, Varghese HJ, MacDonald IC, et al. Inhibition of Angiogenesis in Liver Metastases by Carboxyamidotriazole (CAI): Computer Assisted Analysis. Angiogenesis 1999;2:373–379.

    Article  Google Scholar 

  53. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58–61.

    Article  PubMed  CAS  Google Scholar 

  54. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991;22:339–347.

    PubMed  CAS  Google Scholar 

  55. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277:48–50.

    Article  PubMed  CAS  Google Scholar 

  56. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761–8766.

    Article  PubMed  CAS  Google Scholar 

  57. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999;13:9–22.

    PubMed  CAS  Google Scholar 

  58. Wellner M, Maasch C, Kupprion C, Lindschau C, Luft FC, Haller H. The proliferative effect of vascular endothelial growth factor requires protein kinase C-alpha and protein kinase C-zeta. Arterioscler Thromb Vasc Biol 1999;19:178–185.

    PubMed  CAS  Google Scholar 

  59. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 1998;58:1278–1284.

    PubMed  CAS  Google Scholar 

  60. Kohn EC, Sandeen MA, Liotta LA. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 1992;52:3208–3212.

    PubMed  CAS  Google Scholar 

  61. Figg WD, Cole KA, Reed E, et al. Pharmacokinetics of orally administered carboxyamidotriazole, an inhibitor of calcium-mediated signal transduction. Clin Cancer Res 1995;1:797–803.

    PubMed  CAS  Google Scholar 

  62. Soltis MJ, Yeh HJ, Cole KA, Whittaker N, Wersto RP, Kohn EC. Identification and characterization of human metabolites of CAI [5-amino-1-1(4′-chlorobenzoyl-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide). Drug Metab Dispos 1996;24:799–806.

    PubMed  CAS  Google Scholar 

  63. Berlin J, Tutsch KD, Arzoomanian RZ, et al. Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. Clin Cancer Res 2002;8:86–94.

    PubMed  CAS  Google Scholar 

  64. Kohn EC, Figg WD, Sarosy GA, et al. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 1997;15:1985–1993.

    PubMed  CAS  Google Scholar 

  65. Kohn EC, Reed E, Sarosy G, et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1996;56:569–573.

    PubMed  CAS  Google Scholar 

  66. Hussain M, Sarosy G, Kotz H, et al. A phase II trial of carboxyamidotriazole (CAI) In Patients with refractory eithelial ovarian cancer. Proceedings of the Association for Cancer Research, 93rd Annual Meeting, San Francisco, CA, 2002.

    Google Scholar 

  67. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183–2193.

    PubMed  Google Scholar 

  68. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405–410.

    PubMed  CAS  Google Scholar 

  69. Rose PG, Fusco N, Fluellen L, Rodriguez M. Tolerance of twenty-four hour paclitaxel and carboplatin as first-line therapy in ovarian, peritoneal and fallopian tube carcinoma. Int J Gynecol Cancer 1999;9:448–451.

    Article  PubMed  Google Scholar 

  70. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530–1533.

    Article  PubMed  CAS  Google Scholar 

  71. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992;10:243–248.

    PubMed  CAS  Google Scholar 

  72. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987–993.

    PubMed  CAS  Google Scholar 

  73. Kohn EC, Reed E, Sarosy GA, et al. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res 2001;7:1600–1609.

    PubMed  CAS  Google Scholar 

  74. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748–1753.

    PubMed  CAS  Google Scholar 

  75. Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 1997;24:S62–S67.

    CAS  Google Scholar 

  76. Uziely B, Groshen S, Jeffers S, et al. Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. Ann Oncol 1994;5:827–833.

    PubMed  CAS  Google Scholar 

  77. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994;86:18–24.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Signaling Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD

    Chad M. Michener MD & Elise C. Kohn MD

Authors
  1. Chad M. Michener MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elise C. Kohn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

    Gary K. Schwartz MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Michener, C.M., Kohn, E.C. (2005). Carboxyamidotriazole, an Inhibitor of Nonvoltage-Operated Calcium Entry. In: Schwartz, G.K. (eds) Combination Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-864-1:089

Download citation

  • DOI: https://doi.org/10.1385/1-59259-864-1:089

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-200-1

  • Online ISBN: 978-1-59259-864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation